This educational activity will feature an expert-led discussion about key clinical data surrounding the use of immune checkpoint inhibitors (ICIs), both as monotherapy and in combination with chemotherapy, to manage patients with advanced non-small cell lung cancer (NSCLC) without actional genomic alterations. In addition to covering data surrounding clinical efficacy of ICIs, expert faculty will also describe immune-related adverse events that must be monitored for and mitigated as they arise.

RELEASED DATE: October 31, 2024
EXPIRATION DATE: October 31, 2025

This interactive enduring activity is designed to educate healthcare professionals on the evidence-based implementation of immune checkpoint inhibitors into the management of patients with non-small cell lung cancer (NSCLC). A special emphasis will be placed on how to optimize care across a multidisciplinary and community-based oncology care team, using a patient-centered approach augmented by shared decision-making practices.

RELEASED DATE: December 20, 2024
EXPIRATION DATE: December 20, 2025